We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Calcium Supplements Protects Against Colorectal Adenomas

By Biotechdaily staff writers
Posted on 14 Feb 2007
Earlier research has demonstrated that people with noncancerous colorectal tumors called adenomas who take calcium supplements for four years can reduce their risk of an adenoma recurrence. More...
A new study shows that the protective effect of those supplements lasts for up to five years after stopping supplementation.

In the Calcium Polyp Prevention Study, 930 individuals with a recent adenoma were randomly assigned to receive 4 years of daily 1200-mg calcium supplements or a placebo. The study revealed that those assigned to calcium supplements had a 17% lower relative risk of an adenoma recurrence than those who got the placebo.

In the study, which was published in the January 17, 2007, issue of the Journal of the [U.S.] National Cancer Institute, Maria V. Grau, M.D., John A. Baron, M.D., and colleagues from Dartmouth Medical School (Hanover, NH, USA) tracked 822 of the patients from that trial after the end of the treatment. Their goal was to compare the risk of recurrence among participants who had taken calcium with the risk among those who had taken a placebo.

The researchers discovered that, in the first five years after the end of the treatment, individuals in the calcium group continued to have a lower risk of adenomas than those in the placebo group: 31.5% of people who had taken calcium had recurrences compared with 43.2% of those originally in the placebo group. However, after five years, this protective effect disappeared.

"Our study provides further evidence of the potential of calcium as a chemopreventive agent against colorectal adenomas among individuals with a history of these tumors,” the investigators wrote in their article. "Our data indicate that, in these patients, the protective effect of calcium may extend for up to five years after the cessation of active treatment.”

"Where do we go from here--and, more important, what public health recommendations related to calcium do we provide for risk reduction of colorectal cancer?” asked Maria Elena Martinez, Ph.D., and Elizabeth T. Jacobs, Ph.D., from the Arizona Cancer Center (Tucson, AZ, USA) who wrote an editorial piece in the same issue of the journal. They noted that current guidelines recommend that people only consume recommended levels of calcium (1000 mg/day for adults up to age 50 years and 1,200 mg/day for those older than 50 years). "Because no protection for colorectal cancer is apparent at higher levels of calcium intake, this recommendation is justified,” they wrote.




Related Links:
Dartmouth Medical School

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.